BRCA2 Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

BRCA2 Polyklonal Antikörper für ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IHC, ELISA

Konjugation

Unkonjugiert

Publikationen(15)

Kat-Nr. : 19791-1-AP

Synonyme

BRCA2, BRCC2, breast cancer 2, early onset, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1

---

• 

  WB analysis of HeLa using 19791-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 19791-1-AP (BRCA2 antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

---

Geprüfte Anwendungen

Veröffentlichte Anwendungen

• KD/KO: See 1 publications below
• WB: See 12 publications below
• IHC: See 3 publications below

Produktinformation

19791-1-AP bindet in WB, IHC, ELISA BRCA2 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: Peptid
• Vollständiger Name: breast cancer 2, early onset
• Berechnetes Molekulargewicht: 384 kDa
• GenBank-Zugangsnummer: NM_000059
• Gene symbol: BRCA2
• Gene ID (NCBI): 675
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

BRCA2, also named as FACD and FANCD1, is involved in double-strand break repair and/or homologous recombination. BRCA2 may participate in S phase checkpoint activation. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer (BC) which also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2).

Publikationen

Species	Application	Title
human	WB	Nucleic Acids Res; LncRNA lnc-RI regulates homologous recombination repair of DNA double-strand breaks by stabilizing RAD51 mRNA as a competitive endogenous RNA.; Authors - Liping Shen
human	WB	Int J Biol Macromol; Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation; Authors - Hong-Yu Tao
human	WB	Elife; LIN37-DREAM prevents DNA end resection and homologous recombination at DNA double-strand breaks in quiescent cells; Authors - Bo-Ruei Chen
human	WB	J Med Chem; Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA; Authors - Limei Ji
human	WB	Pharmacol Res; FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.; Authors - Shi-Qi Wu
human	WB	Mol Cancer; The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy.; Authors - Yan Wang ; KD Validated